Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
73.01
-4.66 (-6.00%)
At close: Nov 20, 2026, 4:00 PM EST
72.85
-0.16 (-0.22%)
After-hours: Nov 20, 2026, 6:09 PM EST
Tarsus Pharmaceuticals Revenue
Tarsus Pharmaceuticals had revenue of $194.57M in the quarter ending September 30, 2026, with 63.92% growth. This brings the company's total for the last twelve months to $682.20M, up 86.34% year-over-year. In the year 2025, Tarsus Pharmaceuticals had annual revenue of $451.36M with 146.71% growth. That makes Tarsus Pharmaceuticals the 9,544th largest company in the world by revenue and 2,081st in the United States.
Revenue (ttm)
$682.20M
Revenue Growth
+86.34%
P/S Ratio
5.27
Revenue / Employee
$1,843,792
Employees
370
Market Cap
3.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 451.36M | 268.41M | 146.71% |
| Dec 31, 2024 | 182.95M | 165.51M | 948.62% |
| Dec 31, 2023 | 17.45M | -8.37M | -32.42% |
| Dec 31, 2022 | 25.82M | -31.21M | -54.73% |
| Dec 31, 2021 | 57.03M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Arcutis Biotherapeutics | 508.68M |
| Iovance Biotherapeutics | 378.98M |
| AbCellera Biologics | 67.85M |
| Tango Therapeutics | 53.81M |
| CRISPR Therapeutics AG | 25.17M |
| Relay Therapeutics | 10.35M |
| Xenon Pharmaceuticals | 7.50M |
TARS News
- 10 days ago - Tarsus Pharmaceuticals Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 14 days ago - Tarsus Pharmaceuticals price target raised to $102 from $94 at Mizuho - TheFly
- 15 days ago - Tarsus to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Tarsus Pharmaceuticals price target raised to $97 from $89 at Guggenheim - TheFly
- 16 days ago - Tarsus Pharmaceuticals price target raised to $103 from $100 at Oppenheimer - TheFly
- 16 days ago - Tarsus Pharmaceuticals price target raised to $106 from $88 at H.C. Wainwright - TheFly
- 17 days ago - Tarsus Pharmaceuticals reports Q3 EPS ($14.40), consensus ($3.04) - TheFly
- 17 days ago - Tarsus Pharmaceuticals Earnings Call Transcript: Q3 2026 - Transcripts